PDF) Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

Statins, Fibrates and Myopathy: Pathophysiological Mechanism, Risk Factors and Laboratory Markers

bok%3A978-1-4939-0515-7.pdf ?auth66=1397940469_51b8ba57efa3ddcad3f8aa303951bc25&ext=

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

Dyslipidaemia in type 2 diabetes: cardiovascular risk assessment and management

2018 Guidelines for the management of dyslipidemia

Phenotype Standardization for Statin‐Induced Myotoxicity - Alfirevic - 2014 - Clinical Pharmacology & Therapeutics - Wiley Online Library

Diagnostics, Free Full-Text

Myopathy with statin–fibrate combination therapy: clinical considerations

Impact of critical illness on cholesterol and fatty acids: insights into pathophysiology and therapeutic targets, Intensive Care Medicine Experimental

The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents: A Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association Clinical Practice Update - Canadian Journal of Cardiology

Muscle- and skeletal-related side-effects of statins: tip of the iceberg? - Johann Auer, Helmut Sinzinger, Barry Franklin, Robert Berent, 2016